Document is current
Any future updates will be listed below
-
Authors
Roig Adam, A. https://orcid.org/0000-0003-4515-8365
van Berkel, A. A.
Vanheusden, M. https://orcid.org/0009-0004-3036-4208
Bast, L. https://orcid.org/0000-0001-8489-3923
Smit, A. B. https://orcid.org/0000-0002-2286-1587
Sullivan, P. F. https://orcid.org/0000-0002-6619-873X
Hjerling-Leffler, J. https://orcid.org/0000-0002-4539-1776
Verhage, M. https://orcid.org/0000-0002-6085-7503
- License Information
-
More Information
Article History
Received: 12 June 2025
Revised: 12 August 2026
Accepted: 2 September 2026
First Online: 21 September 2026
Ethics
Competing interests: MVer is paid consultant for four biotech/pharmaceutical companies operating in the same space as studied here (neurodevelopmental disorders): Innoser/Sylics, BioMarin, Capsida and Bial.
Ethics: All procedures requiring animal handling were performed following Swedish guidelines of animal protection and legislation and approved by the ethical committee for ethical experiments on laboratory animals.
